Abstract: The present invention relates to pyrrolidine compounds for treatment of Xeroderma Pigmentosum (XP), specifically for enhancing DNA repair in a subject suffering from XP.

Abstract: The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.

Abstract: The present invention is directed to hMC1R and hMC4R agonist compounds such as afamelanotide, bremelanotide and pharmaceutically acceptable salts thereof for use in treatment of a human subject suffering from cerebrovascular accident (CVA), in particular AIS.

Abstract: The present invention relates to compounds comprising a quaternary ammonium group, their use in skin diseases, and their preparation.

Abstract: The present invention relates to alpha-MSH analogue compounds for treatment of Xeroderma Pigmentosum (XP), specifically for repairing DNA in a subject suffering from XP.

Abstract: The present invention relates to compounds comprising a quaternary ammonium group, their use in skin diseases, and their preparation.

Abstract: The present invention relates to compounds comprising a quaternary ammonium group, their use in skin diseases, and their preparation.

Abstract: The present invention relates to compounds comprising a quaternary ammonium group, their use in skin diseases, and their preparation.

Abstract: The present invention relates to an alpha-MSH analogue compound, the use in skin diseases, and the preparation.

Abstract: The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.

Abstract: The present invention is directed to alpha-MSH analogues for treatment of inflammatory disease.

Abstract: The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analog either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.

Abstract: The present invention is directed to alpha-MSH analogues for treatment of neurodegenerative disorders.

Abstract: A method for treatment to reduce the incidence or rate of development of skin cancers and related conditions caused by or exacerbated by or associated with UVR-induced skin damage in an immuno-compromised subject, such as an organ transplant patient, comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to protect the skin of the subject from UVR-induced skin damage.

Abstract: The present invention relates to a compound having a structure selected from: Ac-Nle-Glu-His-D-Phe-Arg-Trp-NH2 (SEQ ID NO: 1); or Ac-Nle-Gln-His-D-Phe-Arg-Trp-NH2 (SEQ ID NO: 2) or a pharmaceutically acceptable salt thereof. The compound of the salt thereof are particularly useful for the repair or prevention of damage of cellular DNA of dermal (skin) cells following UV irradiation in a mammal.

Abstract: This invention relates to a method for prophylactic or therapeutic treatment of photodermatoses that are caused or exacerbated by or associated with UVR exposure in a subject, particularly a human subject, which comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to reduce the photosensitivity of the skin of the subject.

Abstract: The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.

Abstract: A method for treatment to reduce the incidence or rate of development of skin cancers and related conditions caused by or exacerbated by or associated with UVR-induced skin damage in an immuno-compromised subject, such as an organ transplant patient, comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to protect the skin of the subject from UVR-induced skin damage.

Abstract: The invention relates to a device that maybe used in maxillofacial surgery and dentistry. The device comprises a translating bracket with a cylinder and a fixed bracket with a chamber. A distraction screw is mounted through the cylinder and with one end resting on the chamber. By turning this screw when the device has been mounted on bone pieces osteogenesis can be achieved. The device can be made suitable for both dentulous and edentulous patients with alveolar defects.

Abstract: The invention concerns a radial osteogenic distractor device comprising a stationary member (1) and at least one translating member (2, 2?), the at least one translating member (2; 2?) being slidable within at least one inner lateral channel (10; 21, 22) of the stationary member (1), both the stationary and translating members (1, 2; 2?) being provided with respective fixation holes (3) for fixation to an underlying bone, wherein means (5, 8, 12, 13) are provided at an inner edge of the at least one transtating member (2, 2?) which is opposite to a lateral edge (6) of the at least one translating member (2, 2?) facing the at least one channel (10; 21, 22) of the stationary member (1) to displace the at least one translating member (2, 2?) within the at least one channel (10; 21, 22) in respect to the stationary member (1).